Navigation Links
Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
Date:3/16/2010

Under the Hatch-Waxman Act, Shire has 45 days from the receipt of the Notice Letter to determine if it will file a patent infringement suit. If Shire brings suit pursuant to the Hatch Waxman regulations, a stay of approval of up to 30-months will be imposed by the FDA on Teva's ANDA.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.


'/>"/>
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shire Supports Rare Disease Day 2010
2. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
3. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
4. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
5. New Shire Board Member
6. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
7. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
8. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
9. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
10. Shire Initiates Two Adult ADHD Outreach Programs
11. Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Supplementing their complete line ... for Eppendorf Safe Lock Centrifuge Tubes . ... highest quality tubes at an affordable price. Eppendorf ... doing chemical, medical, pharmaceutical, and life science research ... regularly able to afford Eppendorf products. , Eppendorf ...
(Date:8/27/2014)... 2014 In 2013, Lawrence ... Livermore National Security LLC (LLNS), was awarded ... a state-of-the-art laser system for the European Union's ... construction in the Czech Republic. , When commissioned ... called the " High repetition-rate Advanced Petawatt Laser ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Chelating ... About Chelating Agent A chelating ... covalent bonds with metal ions, thereby forming a ... some metal-ions have on chemical processes, formulations, and ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
Breaking Biology Technology:Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2
... Inc. (TSX: ONC, NASDAQ: ONCY ) ... combination REOLYSIN(R) and docetaxel clinical trial for patients ... trial is Professor Hardev Pandha of the Royal ... at the Fifth International Meeting on Replicating Oncolytic ...
... marginalized groups including the mentally ill, the disabled ... fare worse than others in the aftermath of ... , Now, a new study by UCLA ... greater terrorism-related fears and make more behavioral changes based ...
... power, and much of that juice comes from fuel cells. ... to find more efficient ways to power them. , In ... metal, is a strong candidate for providing that initial boost ... another popular fuel cell catalyst, platinum, and it,s more abundant. ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting 2Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting 3Disabled and other vulnerable groups more susceptible to terrorism fears 2Brown chemists create more efficient palladium fuel cell catalysts 2
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
(Date:8/27/2014)... associated with outcomes after the repair of peripheral ... mechanism of injury, nerve injured, injury location, defect ... repair materials. However, despite numerous studies of outcomes ... is no agreement regarding the independent predictors of ... the predictors has not been quantified. A study ...
(Date:8/27/2014)... Warwick research finds , Gamblers show the same ... research has shown. , Researchers, led by Dr Elliot ... conducted tests that found that both human gamblers and ... than low-value rewards. , Published in Biology Letters ... the important role that memories of previous biggest wins ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Gamblers are greedy bird-brains, University of Warwick research finds 2
... of Biologists is pleased to announce BIOLOGY OPEN (BiO), ... research across all aspects of the biological sciences including ... journal aims to provide rapid publication for peer reviewed, ... fields. BIOLOGY OPEN will address some big issues ...
... a big effect on their life. Some people are ... which can be detrimental to their health and wellbeing. ... , A new study led by Dr Kathryn ... York has added important experimental evidence showing that animal ...
... fish, one from a Caribbean island and one from the Yucatan ... known in any organism, according to a new UC Davis study. ... Venezuela -- and they are all pretty much the same, said ... with Peter Wainwright, a professor of evolution and ecology at UC ...
Cached Biology News:Announcing BIOLOGY OPEN from the Company of Biologists 2Animals have personalities, too 2'Explosive' evolution in pupfish 2
... for enhanced translation of cloned sequences in vitro ... The maps for pCITE-2b(+) and pCITE-2c(+) are the ... is a 3793 bp plasmid; it lacks Nde ... sites. Subtract 7 bp from all sites beyond ...
Anti-NCAPD3 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunoprecipitation, Western Blot...
...
... Slotted migration Chamber lid allows easy ... One-touch connectors for easy set up between ... safety-switch prevents current flow if the lid is ... safety and durability., Remote control can ...
Biology Products: